{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000157","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.019684+00:00","generated_at":"2026-05-31T11:18:40.180584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO","bullets":["Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.","Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.","Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.","John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.","Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000157","json":"https://secwatch.observer/filing/0001867096-24-000157.json","markdown":"https://secwatch.observer/filing/0001867096-24-000157.md","text":"https://secwatch.observer/filing/0001867096-24-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/0001867096-24-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/xers-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:18:40.180584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}